keyword
MENU ▼
Read by QxMD icon Read
search

Xeloda

keyword
https://www.readbyqxmd.com/read/27756893/first-left-hepatic-trisectionectomy-including-segment-one-with-new-associated-liver-partition-and-portal-vein-ligation-with-staged-hepatectomy-alpps-modification-how-to-do-it
#1
Aiman Obed, Anwar Jarrad, Abdalla Bashir
BACKGROUND Associated Liver Partition and Portal vein ligation with Staged hepatectomy (ALPPS) leads to rapid hepatic hypertrophy and decreases incidence of post-hepatectomy liver failure in patients with a marginal future liver remnant. Various procedural ALPPS modifications were previously described. Here, we present the first case of a new ALPPS modification, carrying out a left hepatic trisectionectomy with segment 1. CASE REPORT We present the case of a 36-year-old woman with locally advanced sigmoid adeno-carcinoma and extensive left liver metastases extending to segment V and VIII, who received state-of-the-art systemic conversion chemotherapy...
October 19, 2016: American Journal of Case Reports
https://www.readbyqxmd.com/read/27354816/comparison-of-the-effectiveness-and-toxicity-of-neoadjuvant-chemotherapy-regimens-capecitabine-epirubicin-cyclophosphamide-vs-5-fluorouracil-epirubicin-cyclophosphamide-followed-by-adjuvant-capecitabine-docetaxel-vs-docetaxel-in-patients-with-operable-breast
#2
Minmin Zhang, Wei Wei, Jianlun Liu, Huawei Yang, Yi Jiang, Wei Tang, Qiuyun Li, Xiaoming Liao
The aim of this study was to compare the effectiveness and toxicity of neoadjuvant chemotherapy regimens, xeloda/epirubicin/cyclophosphamide (XEC) vs 5-fluorouracil/epirubicin/cyclophosphamide (FEC), followed by adjuvant chemotherapy regimens, capecitabine/taxotere (XT) vs taxotere (T), in axillary lymph node (LN)-positive early-stage breast cancer. In this randomized, Phase III trial, 137 patients with operable primary breast cancer (T2-0, N0-1) who were tested axillary LN positive through aspiration biopsy of axillary LNs were randomized (1:1) to four 3-weekly cycles of XEC or FEC...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27273944/results-of-third-generation-epirubicin-cisplatin-xeloda-adjuvant-chemotherapy-in-patients-with-radically-resected-gastric-cancer
#3
Calin Cainap, Viorica Nagy, Andrada Seicean, Alexandra Gherman, Istvan Laszlo, Cosmin Lisencu, Al Hajar Nadim, Anne-Marie Constantin, Simona Cainap
PURPOSE: The purpose of this study was to evaluate the efficacy and toxicity of a third-generation chemotherapy regimen in the adjuvant setting to radically operated patients with gastric cancer. This proposed new adjuvant regimen was also compared with a consecutive retrospective cohort of patients treated with the classic McDonald regimen. METHODS: Starting in 2006, a non-randomized prospective phase II study was conducted at the Institute of Oncology of Cluj-Napoca on 40 patients with stage IB-IV radically resected gastric adenocarcinoma...
March 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/27117193/detection-of-capecitabine-xeloda%C3%A2-on-the-skin-surface-after-oral-administration
#4
Mao-Dong Huang, Harald Fuss, Jürgen Lademann, Stefan Florek, Alexa Patzelt, Martina C Meinke, Sora Jung
Palmoplantar erythrodysesthesia (PPE), or hand-foot syndrome, is a cutaneous toxicity under various chemotherapeutics contributing to the most frequent side effects in patients treated with capecitabine (Xeloda®). The pathomechanism of PPE has been unclear. Here, the topical detection of capecitabine in the skin after oral application was shown in 10 patients receiving 2500  mg/m 2 /day 2500  mg/m2/day capecitabine. Sweat samples were taken prior to and one week after oral administration of capecitabine...
April 30, 2016: Journal of Biomedical Optics
https://www.readbyqxmd.com/read/26929778/a-novel-schedule-of-erlotinib-capecitabine-7-7-as-salvage-therapy-in-previously-treated-advanced-pancreatic-adenocarcinoma-a-case-series
#5
Jiezhong Chen, Kristin Kaley, Marie Carmel Garcon, Teresa Rodriguez, Muhammad Wasif Saif
BACKGROUND: The objective of this study was to report a case series on the efficacy and safety of capecitabine 7/7 schedule combined with erlotinib (CAP-ERL) in patients with advanced pancreatic cancer (APC) who have failed prior therapies. METHODS: We retrospectively evaluated 13 patients with locally advanced or metastatic pancreatic cancer previously treated with gemcitabine or oxaliplatin-irinotecan-based first-line regimens. Treatment consisted of capecitabine (Xeloda) at a flat dose of 1000 mg orally twice daily on days 1-7 out of 14 days (7/7 schedule) and erlotinib (Tarceva) 100 mg orally once daily until unacceptable toxicity or disease progression...
March 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/26805132/-curative-surgery-for-advanced-gastric-cancer-with-extensive-lymph-node-metastasis-after-long-term-chemotherapy
#6
Shotaro Fujita, Tomoyuki Monma, Shinji Ohki, Yuko Murakami, Hirokazu Okayama, Takashi Yazawa, Masashi Takawa, Kensuke Kumamoto, Toru Ohtake, Koji Kono, Seiichi Takenoshita
A 65-year-old man was diagnosed with HER2-positive gastric cancer considered unresectable owing to multiple distant lymph node metastases. After long-term chemotherapy, the original lesion disappeared, while peri-gastric lymph node metastases remained. Therefore, we performed lower mediastinal lymph node dissection, total gastrectomy with regional lymph node dissection (D2) and cholecystectomy. Pathological evaluation indicated that the main gastric tumor showed complete response, while there was metastasis in the No...
November 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/26782354/a-pilot-study-of-an-individualized-comprehensive-treatment-for-advanced-gastric-cancer-with-para-aortic-lymph-node-metastasis
#7
Qi He, Long Ma, Yang Li, Guoli Li
BACKGROUND: The incidence of the para-aortic lymph node metastasis (PALM) in patients with advanced gastric cancer is 6 to 33 %. The prognosis is poor and the 5-year survival rate is only 12 to 23 % after gastrectomy with super-extended lymph node dissection. We applied an individualized comprehensive treatment for affected patients including neoadjuvant chemotherapy via intra-arterial and intravenous administration, surgery and radiotherapy, to investigate the safety and prognostic value...
January 18, 2016: BMC Gastroenterology
https://www.readbyqxmd.com/read/26662434/study-of-the-radiotherapy-sensitization-effects-and-mechanism-of-capecitabine-xeloda-against-non-small-cell-lung-cancer-cell-line-a549
#8
J J Zhu, J J Shan, L B Sun, W S Qiu
The purpose of this study was to explore the radiotherapy sensitization effects and the mechanism of capecitabine (Xeloda) against the non-small-cell lung cancer cell line, A549. γ-[(60)Co] radiation was used as the intervention method. Proliferative inhibition of capecitabine on A549 cells was determined by the CCK-8 method. The effects of capecitabine on the apoptosis rate and cell cycle distribution of A549 were detected with the flow cytometric method. We found that capecitabine inhibited the proliferation of A549 in a dose-dependent manner, notably increased the cell apoptosis rate and blocked the cellular G0/G1 phase after radiotherapy by γ-[(60)Co]...
2015: Genetics and Molecular Research: GMR
https://www.readbyqxmd.com/read/26559272/predictors-of-pathologic-complete-response-in-rectal-cancer-patients-undergoing-total-mesorectal-excision-after-preoperative-chemoradiation
#9
Yoon Dae Han, Woo Ram Kim, Seung Wan Park, Min Soo Cho, Hyuk Hur, Byung Soh Min, Seung Hyuk Baik, Kang Young Lee, Nam Kyu Kim
Preoperative chemoradiotherapy (CRT) is the standard of care for patients with stage II and III rectal cancer. This strategy leads to pathologic complete response (pCR) in a significant number of patients. Factors predictive of pCR are currently being extensively investigated. The aim of this study was to analyze clinical factors that might be predictive of pCR.This study was a retrospective analysis of rectal cancer patients from January 2004 through December 2012. A total of 332 stage II and III patients with middle and low rectal cancer (≤10 cm) who received CRT and underwent curative total mesorectal excision were eligible...
November 2015: Medicine (Baltimore)
https://www.readbyqxmd.com/read/26557901/therapeutic-potential-of-tas-102-in-the-treatment-of-gastrointestinal-malignancies
#10
REVIEW
Godefridus J Peters
Fluoropyrimidines form the mainstay in treatment of gastrointestinal malignancies. For decades 5-fluorouracil (5FU), was the major fluoropyrimidine. Currently it is usually given in a combination with leucovorin and oxaliplatin, i.e. FOLFOX, or irinotecan, i.e. FOLFIRI, or all three, i.e. FOLFIRINOX, but gradually it has been replaced by oral fluoropyrimidine prodrug formulations, such as tegafur-uracil and S-1 (both contain ftorafur), and capecitabine (Xeloda®). Novel drugs such as the antivascular endothelial growth factor antibody, bevacizumab, and the anti-epidermal growth factor receptor antibody, cetuximab, are often combined with one of these treatment options...
November 2015: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/26148595/clinical-study-of-tegafur-gimeracil-oteracil-potassium-capsule-s-1-and-oxaliplatin-combination-chemotherapy-in-advanced-colorectal-cancer
#11
RANDOMIZED CONTROLLED TRIAL
Huaqun Liu, Yigang Wang, Guozhong Li, Wenguang Song, Ruilin Wang
OBJECTIVE: The aim of this study was to evaluate the therapeutic efficacy and toxicity of a combination of tegafur-gimeracil-oteracil potassium capsules (S-1) with oxaliplatin for treatment of advanced or recurrent colorectal cancer. SUBJECTS AND METHODS: Between October 2009 and October 2011, 70 patients at our hospital with advanced or recurrent colorectal cancer were enrolled into our study and divided randomly into two groups: A treatment group (S-1 combined with oxaliplatin) and a control group (Xeloda combined with oxaliplatin)...
April 2015: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/26108774/-clinical-efficacy-observation-of-cetuximab-combined-with-chemotherapy-in-the-treatment-of-metastatic-colorectal-carcinoma
#12
Tingting Zhang, Dan Su, Juan Li, Yishang Wang, Chun Han, Shunchang Jiao, Li Bai
OBJECTIVE: To observe the clinical efficacy of cetuximab plus chemotherapy in the treatment of metastatic colorectal carcinoma. METHODS: Clinicopathological data of 128 patients with metastatic colorectal cancer admitted in the Department of Oncology, Chinese PLA General Hospital from 2008 to June 2012 were analyzed retrospectively. Among them, 91 patients received cetuximab as the first-line therapy and 37 in the second-line or more-line therapy. The chemotherapy regimens included oxaliplatin-based therapy (FOLFOX/XELOX), irinotecan-based therapy (FOLFIRI/XELIRI) and fluorouracil-based therapy (Xeloda)...
June 2015: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/26016146/-immediate-results-of-combined-therapy-for-local-recurrences-of-rectal-cancer
#13
COMPARATIVE STUDY
L I Korytova, A G Sandalevskaya, V G Krasnikoval, O V Korytov, A V Meshechkin
The purpose of this paper was to increase the effectiveness of radiation therapy (RT) of local recurrence of rectal cancer (MRRPK) by setting the preferred modes and dynamic medium dose fractionation irradiation MRRPK, assessing immediate outcomes, identifying the frequency and severity of early radiation reactions during radiation therapy. The study included 60 patients with a diagnosis of "local recurrence of rectal cancer." The median age was 67 years. Terms of recurrence after surgical treatment averaged 20 months...
2015: Voprosy Onkologii
https://www.readbyqxmd.com/read/25987082/clinical-observation-on-recombinant-human-endostatin-combined-with-chemotherapy-for-advanced-gastrointestinal-cancer
#14
Shao-Rong Gao, Lu-Ming Li, Hai-Ping Xia, Guang-Ming Wang, Hong-Yan Xu, Ai-Rong Wang
OBJECTIVE: To explore the clinical efficacy and toxic and side effects of recombinant human endostatin (rh- endostatin/endostar) combined with chemotherapy in the treatment of advanced gastric cancer. MATERIALS AND METHODS: A total of 70 patients with advanced gastrointestinal adenocarcioma confirmed by histopathology and/or cytological examination were divided into group A (37 patients) and group B (33 patients). Patients in group A were given intravenous drip of 15 mg endostar added into 500 mL normal saline, once every other day until the cessation of chemotherapy or patients' maximal tolerance to chemotherapy...
2015: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/25960662/pilot-study-investigating-the-prognostic-significance-of-thymidine-phosphorylase-expression-in-patients-with-metastatic-breast-cancer-a-single-institution-retrospective-analysis
#15
Anna Lisa Tedeschi, Zohreh Eslami, Evgenia Garoufalis, Ramy R Saleh, Atilla Omeroglu, Gulbeyaz Altinel, Maria Ait-Tihyaty, Bertrand Jean-Claude, Catalin Mihalcioiu
BACKGROUND: The thymidine phosphorylase (TP) enzyme is expressed in higher levels in cancer tissue when compared with normal tissue. It is involved in the intratumoral activation of widely prescribed pyrimidine-derived antimetabolites such as 5'-deoxy-5-fluorouridine and capecitabine (Xeloda(®)). The purpose of this study was to determine the clinical correlation between TP expression in tumor tissue and the clinical outcome of capecitabine-based therapy in patients with locally advanced (stage III) or metastatic breast cancer (stage IV)...
2015: OncoTargets and Therapy
https://www.readbyqxmd.com/read/25731548/-a-case-of-locoregional-recurrence-after-gastric-cancer-surgery-which-was-treated-with-xpt-regimen-chemotherapy
#16
Yoshio Oka, Kaoru Okada, Hisashi Uemura, Shigeru Nakane, Yasuhiro Miyake, Naozumi Higaki, Masakazu Murakami, Hirohito Hayashida, Riichiro Nezu
Based on the results of the trastuzumab for gastric cancer (ToGA) trial, the regimen of Xeloda/5-FU+CDDP+trastuzu- mab (XPT/FPT) has become the standard of care for treatment of HER2-positive unresectable or recurrent gastric cancers. In our hospital, the percentage of HER2-positive gastric cancer patients is 16.7%; we present a case of recurrence 26 months after gastric cancer surgery. A 67-year-old man presented with locoregional lymph node recurrence, with swelling in a paraaortic lymph node. ¹⁸F-fluorodeoxy glucose positron emission tomography (FDG-PET) examination revealed abnormal accumulation in these lymph nodes...
November 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/25731501/-a-case-of-her2-positive-advanced-gastric-cancer-with-extensive-lymph-node-metastasis-treated-via-chemotherapy-with-a-trastuzumab-containing-regimen-followed-by-conversion-surgery
#17
Kazuyoshi Yamamoto, Kazumasa Fujitani, Toshimasa Tsujinaka, Motohiro Hirao, Kazuhiro Nishikawa, Yasunari Fukuda, Naotsugu Haraguchi, Masakazu Miyake, Tadafumi Asaoka, Atsushi Miyamoto, Hideyasu Omiya, Masataka Ikeda, Koji Takami, Shoji Nakamori, Mitsugu Sekimoto
A 62-year-old man presented with type 3 gastric cancer (tub1, HER2 positive) in the cardia, with 10-cm direct invasion into the lower esophagus, and extensive lymph node metastasis (Virchow and paraaortic nodes). Trastuzumab (Her), in the XP regimen (capecitabine and cisplatin [CDDP] plus Her; Xeloda®: 2,000 mg/m² on day 1-14, CDDP: 80 mg/m² on day 1, Her: 8(6) mg/kg on day 1), was administered every 3 weeks and repeated for 6 courses. After administering 6 courses of the XP plus Her regimen, without severe adverse events in the patient, computed tomography (CT) revealed shrinkage of both the main tumor and the metastatic sites, by 51%...
November 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/25596695/-suspected-dihydropyrimidine-dehydrogenase-deficiency-in-a-patient-receiving-capecitabine-as-adjuvant-chemotherapy-after-colon-resection
#18
Kentaro Nagai, Yoichi Okuda, Yusuke Ohara, Masayoshi Yamamoto
We report here the case of a 75-year-old male patient who developed severe side effects after treatment with capecitabine (Xeloda®) that he received as adjuvant chemotherapy. He was suspected to have partial dihydropyrimidine dehydrogenase (DPD) deficiency. The patient underwent sigmoidectomy for sigmoid cancer and was treated with capecitabine as adjuvant chemotherapy. He was admitted to our hospital 14 days after the start of treatment with appetite loss, diarrhea, and a high body temperature. After admission, he developed severe neurotoxicity (Grade 4)...
January 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/25531721/quality-of-life-under-capecitabine-xeloda%C3%A2-in-patients-with-metastatic-breast-cancer-data-from-a-german-non-interventional-surveillance-study
#19
MULTICENTER STUDY
Volkmar Müller, Stefan Fuxius, Claus-Christoph Steffens, Christian Lerchenmüller, Birgit Luhn, Ursula Vehling-Kaiser, Ursula Hurst, Lars-Jörgen Hahn, Ulrike Soeling, Tim Wohlfarth, Matthias Zaiss
AIM: This non-interventional surveillance study (NIS) collected data on the quality of life (QoL) of patients treated with capecitabine as mono- or combination chemotherapy in an outpatient setting. METHODS: Capecitabine was administered orally for 14 days of each 21-day cycle. The main parameters of interest were QoL, compliance, patient and physician satisfaction, handling of hand-foot syndrome (HFS), and efficacy. The statistics were descriptive; some differences were compared using confidence intervals (CIs)...
2014: Oncology Research and Treatment
https://www.readbyqxmd.com/read/25461961/hypomagnesemia-and-chemotherapy-diagnostic-dilemma-and-treatment-challenge-case-report-and-literature-review
#20
Nivin Haroon, Syed M Raza, Zeenat Y Bhat
Magnesium is the second most common intracellular cation after potassium and plays pivotal role in the majority of metabolic process. Several studies have shown the prevalence of hypomagnesemia ranging from 2.5% to 12% in general population and even up to 60% in intensive care unit patients. Hypomagnesemia might be more prevalent in patients with cancer owing to a combination of several factors such as gastrointestinal loss, renal loss, poor intake, and use of certain chemotherapeutic drugs. It is imperative that we identify the exact cause of hypomagnesemia to aid and guide treatment...
July 2016: American Journal of Therapeutics
keyword
keyword
62248
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"